title: Safety and pharmacokinetics of a single 1500-mg dose of famciclovir in adolescents with recurrent herpes labialis.
abstract: An open-label study evaluated the safety (n = 53) and pharmacokinetics (n = 8) of single-dose therapy with 1500 mg famciclovir (prodrug of penciclovir) for recurrent herpes labialis in adolescents. Mean Cmax, mean AUC0-∞, and clearance for penciclovir were 9.37 μg/mL, 31.8 μg · h/mL, and 38.2 L/h, respectively, and within the range extrapolated from data in adults. Adverse events were generally mild and transient.
authors.affiliation: Department of Pediatrics, University of Kentucky College of Medicine, Louisville, KY, USA. sblock@pol.net
authors.forename: Stan L
authors.initials: SL
authors.lastname: Block
authors.forename: Ram
authors.initials: R
authors.lastname: Yogev
authors.forename: Felix
authors.initials: F
authors.lastname: Waldmeier
authors.forename: Kamal
authors.initials: K
authors.lastname: Hamed
mesh_terms: D015075:2-Aminopurine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000293:Adolescent; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D002648:Child; D000077595:Famciclovir; D005260:Female; D006560:Herpes Labialis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D012008:Recurrence; D044967:Serum / Q000737:chemistry
chemical_list: D000998:Antiviral Agents; D015075:2-Aminopurine; D000077595:Famciclovir